Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
NCT07059091
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- September 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- University of Arizona- Tuscon · Tucson, AZ
Illinois · 1
- Northwestern University · Chicago, IL
Kansas · 1
- University of Kansas Medical Center · Kansas City, KS
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Michigan · 1
- University of Michigan · Ann Arbor, MI
New York · 1
- Columbia University · New York, NY
Pennsylvania · 2
- Temple University · Philadelphia, PA
- University of Pittsburgh · Pittsburgh, PA
Texas · 1
- Baylor College of Medicine · Houston, TX
Vermont · 1
- University of Vermont · Colchester, VT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.